Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a sell rating to a hold rating in a report released on Sunday morning.

A number of other research firms have also weighed in on ZNTL. Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Leerink Partners reissued a “market perform” rating and set a $2.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Morgan Stanley cut their target price on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus target price of $4.53.

Zentalis Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ:ZNTL opened at $1.36 on Friday. The business’s 50 day moving average is $1.51 and its 200 day moving average is $1.45. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.00. The stock has a market cap of $98.26 million, a price-to-earnings ratio of -0.66 and a beta of 1.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. As a group, equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC lifted its holdings in Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock valued at $4,244,000 after purchasing an additional 1,606,802 shares during the last quarter. Nuveen LLC purchased a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $807,000. Tybourne Capital Management HK Ltd. raised its position in shares of Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after purchasing an additional 516,666 shares during the period. GSA Capital Partners LLP raised its position in shares of Zentalis Pharmaceuticals by 275.9% in the first quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock valued at $862,000 after purchasing an additional 397,805 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter valued at approximately $81,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.